Pfizer’s ABRYSVO is a vaccine to prevent lower respiratory disease from RSV in adults 60 years and older. Pfizer’s ABRYSVO is the first and only vaccine given between 32 through 36 weeks of pregnancy to prevent RSV in babies from birth through 6 months of age.

Oct 30, 2024 · Abrysvo vaccine protects against LRTD (lower respiratory tract disease) caused by the Respiratory Syncytial virus (RSV) in adults aged aged 18 and older with conditions that put them at high risk of LRTD, and all adults aged 60 years and older.

ABRYSVO (Respiratory Syncytial Virus Vaccine) helps protect against respiratory syncytial virus (RSV) in adults 60 years & older.

Oct 23, 2024 · ABRYSVO is indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older, and...

Oct 22, 2024 · ABRYSVO is an unadjuvanted, bivalent vaccine that was designed to provide broad protection against RSV-LRTD, regardless of the virus subgroup. In the prefusion state, the RSV fusion protein (F) is a major target of neutralizing antibodies, serving as the basis of …

See where Pfizer's RSV vaccine ABRYSVO® (Respiratory Syncytial Virus Vaccine) is near you and ask your doctor or pharmacist about it.

ABRYSVO is an RSV vaccine for adults 60 and older who remain unvaccinated. Talk to your pharmacist or doctor to see if ABRYSVO is right for you. What is RSV? RSV (respiratory syncytial virus) is a highly contagious virus that can easily spread by touching a contaminated surface.

ABRYSVO is a vaccine indicated for active immunization of pregnant individuals at 32 through 36 weeks gestational age for the prevention of lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age.

ABRYSVO ® provides your patients aged 60+ powerful protection against RSV 1,2 Choose ABRYSVO to help protect eligible patients from the threat of RSV 1 Efficacy View 2-Season Data Loading Primary endpoints in an RSV clinical trial of ~34,000 adults aged 60 years and older 1 * Symptoms include cough, wheezing, sputum production, shortness of breath, and tachypnea. …

Mar 7, 2025 · Abrysvo is a bivalent, stabilized prefusion F vaccine designed to protect against both major RSV subtypes, RSV-A and RSV-B. It has been approved for use in adults ages 60 and older, those ages 18 to 59 who are at increased risk for RSV-related LRTI and infants through maternal vaccination.